Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clene Inc. - Common Stock (NQ: CLNN )

4.790 -0.100 (-2.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Clene Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS
Via Investor Brand Network
Study Sheds Light on How Mitochondrial Changes Contribute to Muscle Aging
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)
Via Investor Brand Network
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) Improves Cash Position and Runway with New Debt Facility for CNM-Au8(R) Data Collection to Support Accelerated Approval Application
Via Investor Brand Network
Exposures Product Safety
MS Drug Could Counter Poor Working Memory
Via Investor Brand Network
Toxic Protein Could Be Behind the Development of Amyotrophic Lateral Sclerosis
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Secures $10 Million Debt Facility to Advance Neurodegenerative Disease Treatments
Via Investor Brand Network
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) Receives FDA Guidance on Accelerated Approval Pathway for CNM-Au8(R) for ALS
Via Investor Brand Network
Exposures Product Safety
New Technology Programs Immune Cells to Combat Brain Cancer, MS
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances CNM-Au8 in ALS with FDA Guidance on Accelerated Approval Pathway
Via Investor Brand Network
Exposures Product Safety
Disruptions in Purine Metabolism Cited in Parkinson’s Development
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports Q3 2024 Results and Progress on ALS Treatment Pathway
Via Investor Brand Network
Exposures Product Safety
European Commission Imposes Hefty Fine on Firm for Blocking Rival MS Drug Developer
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA Leadership
Via Investor Brand Network
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates, Latest Achievements at Top Investor Conferences
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M
Via Investor Brand Network
Exposures Product Safety
IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M
Via Investor Brand Network
IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8
Via Investor Brand Network
Exposures Product Safety
Does Multiple Sclerosis Reduce Risk of Developing Dementia?
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast
Via Investor Brand Network
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.